Triple Negative Breast Cancer (TNBC) represents one of the most aggressive and challenging subtypes of breast cancer, affecting roughly 10-20% of all cases. Characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, TNBC does not respond to conventional hormonal or HER2-targeted treatments, leaving chemotherapy as the primary option. It particularly imp..